{"protocolSection": {"identificationModule": {"nctId": "NCT00079937", "orgStudyIdInfo": {"id": "CIGE025AIA05"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma", "officialTitle": "A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2012-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-04"}, "primaryCompletionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-03-18", "studyFirstSubmitQcDate": "2004-03-19", "studyFirstPostDateStruct": {"date": "2004-03-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-03", "resultsFirstSubmitQcDate": "2011-07-07", "resultsFirstPostDateStruct": {"date": "2011-08-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-04-09", "lastUpdatePostDateStruct": {"date": "2012-04-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.", "detailedDescription": "This study was designed to provide one year efficacy and safety data for subcutaneous (SC) omalizumab, compared to placebo in children (6 to \\< 12 years) with moderate to severe persistent asthma who have inadequate asthma control despite treatment according to National Heart, Lung and Blood Institute (NHLBI) step 3 or 4 (at least medium dose inhaled corticosteroids with or without other controller asthma medications)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["allergic", "asthma", "atopic", "omalizumab", "immunoglobulin E", "IgE", "anti-IgE"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 628, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab", "type": "EXPERIMENTAL", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.", "interventionNames": ["Drug: Omalizumab", "Drug: Fluticasone"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.", "interventionNames": ["Drug: Placebo", "Drug: Fluticasone"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.", "armGroupLabels": ["Omalizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Fluticasone", "description": "Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) \u2265 200 \u03bcg/day equivalent of fluticasone administered with a dry-powder inhaler.", "armGroupLabels": ["Omalizumab", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma symptoms, as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose and/or treatment with systemic rescue corticosteroids for at least 3 days. The exacerbations rate per patient was derived using Poisson model adjusted by time at risk and the following covariates: country, exacerbation history, and dose schedule. A patient's person-days at risk was taken as the total amount of time (in days) he/she spent in the 24-week fixed-dose steroid treatment period.", "timeFrame": "Baseline to end of the fixed-dose steroid treatment period (Week 24)"}, {"measure": "Percentage of Participants With at Least 1 Adverse Event", "description": "See Adverse Events module for details.", "timeFrame": "Baseline to end of the study (Week 68)"}], "secondaryOutcomes": [{"measure": "Change in Mean Nocturnal Asthma Symptom Score From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period", "description": "Nocturnal asthma symptom was measured daily on a scale of 0 to 4 in response to the question \"How did you sleep last night?\", with 0 as the best response and 4 as the worst response. The mean of the last 4 weeks of the 24-week fixed-dose steroid treatment period was calculated; for patients who discontinued prematurely, the mean of the last 28 days before discontinuation was calculated. A negative change in mean score indicated improvement.", "timeFrame": "Baseline to the end (last 4 weeks) of the 24-week fixed-dose steroid treatment period"}, {"measure": "Rate of Clinically Significant Asthma Exacerbations Per Patient in the 52-week Treatment Period", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma symptoms, as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose and/or treatment with systemic rescue corticosteroids for at least 3 days. The exacerbations rate per patient was derived using Poisson model adjusted by time at risk and the following covariates: country, exacerbation history, and dose schedule. A patient's person-days at risk was taken as the total amount of time (in days) he/she spent in the 52-week treatment period.", "timeFrame": "Baseline to end of the treatment period (Week 52)"}, {"measure": "Change in Mean Daily Number of Puffs of Asthma Rescue Medication From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period", "description": "Patients were instructed to record the number of puffs of rescue medication they took twice daily in a diary. The mean daily number of puffs during the last 4 weeks of the 24-week fixed-dose steroid treatment period was calculated; for patients who discontinued prematurely, the mean of the last 28 days before discontinuation was calculated. A negative change in mean daily number of puffs indicated reduced use of rescue medication.", "timeFrame": "Baseline to the end (last 4 weeks) of the 24-week fixed-dose steroid treatment period"}, {"measure": "Change in Pediatric Asthma Quality of Life Questionnaire (Standardized) [PAQLQ(S)] Scores From Baseline to the End of the 24-week Fixed-dose Steroid Treatment Period (Week 24)", "description": "PAQLQ measures functional problems that are most troublesome to children with asthma. PAQLQ has 23 questions in 3 domains (activity limitation=5, emotional function=8, symptoms=10). Patients responded to each question on a 7-point Likert scale. Overall PAQLQ score is mean of 23 questions; each domain score is mean of questions in that domain. Minimum possible value is 1 (maximum impairment); maximum possible value is 7 (no impairment). Positive change indicated improvement. The analysis included country, baseline PAQLQ value, and dosing schedule (2-weekly/4-weekly) as factors and covariates.", "timeFrame": "Baseline to the end of the 24-week fixed-dose steroid treatment period (Week 24)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Parent or legal guardian was informed of the study procedures and medications and gave written informed consent.\n* Outpatient males and females aged 6 - \\< 12 years on study entry, with body weight between 20 and 150 kg.\n* Total serum IgE level \u2265 30 to \u2264 1300 IU.\n* Diagnosis of allergic asthma \u2265 1 year duration, according to American Thoracic Society (ATS) criteria, and a screening history consistent with clinical features of moderate or severe persistent asthma according to National Heart Lung and Blood Institute (NHLBI) guidelines.\n* Positive prick skin test to at least one perennial allergen, documented within the past 2 years or taken at Screening. A radioallergosorbent test (RAST) could have been performed for patients with a borderline skin prick test result after consultation with Novartis clinical personnel.\n* Patients with \u2265 12% increase in forced expiratory volume in 1 second (FEV1) over starting value within 30 minutes of taking up to 4 puffs (4x100 \u00b5g) salbutamol (albuterol) or nebulized salbutamol up to 5 mg (or equivalent of alternative B2-agonist) documented within the past year, at screening, during the run-in period, or prior to randomization. Patients were not to take their long acting B2-agonist (LABA) medication within 12 hours of reversibility testing.\n* Clinical features of moderate or severe persistent asthma (at least step 3) despite therapy at step 3 or 4 (at least medium dose inhaled corticosteroid (ICS) - fluticasone dry-powder inhaler (DPI) \u2265 200 mg/day or equivalent with or without other controller medications).\n* Documented history of experiencing asthma exacerbations and demonstrated inadequate symptom control during the last 4 weeks of run-in despite receiving an equivalent dose of fluticasone DPI \u2265 200 mg/day total daily ex-valve dose.\n\nExclusion criteria:\n\n* Patients who received systemic corticosteroids for reasons other than asthma, beta-adrenergic antagonists by any route, anticholinergics within 24 hours of Screening, methotrexate, gold salts, cyclosporin or troleandomycin, or had received desensitization therapy with less than 3 months of stable maintenance doses prior to Screening.\n* Patients with a history of food or drug related severe anaphylactoid or anaphylactic reaction, a history of allergy to antibiotics, with aspirin or other non-steroidal anti-inflammatory drugs (NSAID)-related asthma (unless the NSAID could be avoided), with active lung disease or acute sinusitis/chest infection, elevated serum IgE levels for other reasons, presence/history of a clinically significant uncontrolled systemic disease, cancer, abnormal, electrocardiogram (ECG) in the previous month, or platelets \u2264 100 x 109/L or clinically significant laboratory abnormalities at Screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Alabama Allergy and Asthma Center", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "University of Arkansas for Medical Sciences", "city": "Little Rock", "state": "Arkansas", "zip": "72202", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Clinical Research Center", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Allergy and Asthma Specialists Medical Group", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Pediatric Care and Medical Group", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "West Coast Clinical Trials", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Southern California Research Center", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Children's Hosptial of Orange County, Div Asthma, Allergy & Immunology", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "CA Allergy & Asthma Med Group", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Dr. Joann Blessing-Moore", "city": "Palo Alto", "state": "California", "zip": "94304", "country": "United States", "geoPoint": {"lat": 37.44188, "lon": -122.14302}}, {"facility": "Integrated Research Group", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Allergy Associates Medical Group", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Allergy and Asthma Medical Group & Research Center", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Allergy and Asthma Associates of Santa Clara Valley RC", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "1304 15th St", "city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"facility": "Bensch Research Associates", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Allergy & Asthma Med Group of Diablo Valley CR", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "National Jewish Medical and Research Center", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Miami Children's Hospital", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Georgia Pollens", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Family Allergy and Asthma Center, PC", "city": "Atlanta", "state": "Georgia", "zip": "30342", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Aeroallergy Research Labs of Savannah, Inc", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Rush University Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Asthma & Allergy Center", "city": "Elliott City", "state": "Maryland", "zip": "21042", "country": "United States", "geoPoint": {"lat": 39.26733, "lon": -76.79831}}, {"facility": "Northeast Med Research Associates", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "St. Louis University School of Medicine", "city": "St. Louis", "state": "Missouri", "zip": "63104", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Midwest Allergy & Asthma Clinic", "city": "Omaha", "state": "Nebraska", "zip": "68114", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Ocean Allergy & Respiratory Research Center", "city": "Brick", "state": "New Jersey", "zip": "08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "UMDNJ", "city": "Newark", "state": "New Jersey", "zip": "07101", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "Womes And childrens Hospital of Buffalo", "city": "Buffalo", "state": "New York", "zip": "14222", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Asthma & Allergy Associates", "city": "Ithaca", "state": "New York", "zip": "14850", "country": "United States", "geoPoint": {"lat": 42.44063, "lon": -76.49661}}, {"facility": "Allergy and Asthma Diagnostic Office", "city": "Liverpool", "state": "New York", "zip": "13088", "country": "United States", "geoPoint": {"lat": 43.10646, "lon": -76.2177}}, {"facility": "Island Medical Research (Allergy and Asthma Center)", "city": "Rockville Center", "state": "New York", "zip": "11570", "country": "United States"}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Allergy & Asthma Center of North carolina", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Bernstein Clinical Research Center", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Resp Dis of Children and Adolescents", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Clinical Research Institute of Southern Oregon", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "501 Howard Av", "city": "Altoona", "state": "Pennsylvania", "zip": "16601", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "West Penn Allegheny General Health System", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Asthma and Allergy Associates", "city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "AAPRI Clinical Research Institute", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Allergy Assoc., The ASthma, Allergy & Sinus Ctr", "city": "Knoxville", "state": "Tennessee", "zip": "37922", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Vanderbilt University", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Pediatric Allergy/Immunology Associates, PA", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Pediatric Pulmonary Association of North Texas", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "North Texas Institute for Clinical Trials", "city": "Ft. Worth", "state": "Texas", "zip": "76132", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "7707 Fannin/Ste. 195", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Sylvanna Research", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Copperview Medical Center", "city": "South Jordan", "state": "Utah", "zip": "84095", "country": "United States", "geoPoint": {"lat": 40.56217, "lon": -111.92966}}, {"facility": "Childrens Hospital of the Kings Daughters", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Virgina Commonwealth", "city": "Richmond", "state": "Virginia", "zip": "23219", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "A.S.T.H.M.A., Inc.", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "508 W 6th Av", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Medical College of Wisconsin", "city": "Milwaukee", "state": "Wisconsin", "zip": "53226", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}, "referencesModule": {"references": [{"pmid": "33223095", "type": "DERIVED", "citation": "Busse WW, Szefler SJ, Haselkorn T, Iqbal A, Ortiz B, Lanier BQ, Chipps BE. Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1201-1211. doi: 10.1016/j.jaip.2020.10.027. Epub 2020 Oct 24."}, {"pmid": "32298853", "type": "DERIVED", "citation": "Szefler SJ, Casale TB, Haselkorn T, Yoo B, Ortiz B, Kattan M, Busse WW. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2673-2680.e3. doi: 10.1016/j.jaip.2020.03.033. Epub 2020 Apr 13."}, {"pmid": "19910033", "type": "DERIVED", "citation": "Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009 Dec;124(6):1210-6. doi: 10.1016/j.jaci.2009.09.021."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "FG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "421"}, {"groupId": "FG001", "numSubjects": "207"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "352"}, {"groupId": "FG001", "numSubjects": "175"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Subject no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "BG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "421"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "628"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.7", "spread": "1.7"}, {"groupId": "BG001", "value": "8.4", "spread": "1.7"}, {"groupId": "BG002", "value": "8.6", "spread": "1.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "203"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "287"}, {"groupId": "BG001", "value": "138"}, {"groupId": "BG002", "value": "425"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "99"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "249"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "377"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "103"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "150"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Change in Mean Nocturnal Asthma Symptom Score From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period", "description": "Nocturnal asthma symptom was measured daily on a scale of 0 to 4 in response to the question \"How did you sleep last night?\", with 0 as the best response and 4 as the worst response. The mean of the last 4 weeks of the 24-week fixed-dose steroid treatment period was calculated; for patients who discontinued prematurely, the mean of the last 28 days before discontinuation was calculated. A negative change in mean score indicated improvement.", "populationDescription": "Modified intent-to-treat population: All patients who were randomized, excluding patients from 2 sites due to Good Clinical Practice non-compliance. Excluded patients were replaced with patients at other sites to maintain statistical power.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline to the end (last 4 weeks) of the 24-week fixed-dose steroid treatment period", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "382"}, {"groupId": "OG001", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.72"}, {"groupId": "OG001", "value": "-0.50", "spread": "0.71"}]}]}]}, {"type": "PRIMARY", "title": "Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma symptoms, as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose and/or treatment with systemic rescue corticosteroids for at least 3 days. The exacerbations rate per patient was derived using Poisson model adjusted by time at risk and the following covariates: country, exacerbation history, and dose schedule. A patient's person-days at risk was taken as the total amount of time (in days) he/she spent in the 24-week fixed-dose steroid treatment period.", "populationDescription": "Modified intent-to-treat population: All patients who were randomized, excluding patients from 2 sites due to Good Clinical Practice non-compliance. Excluded patients were replaced with patients at other sites to maintain statistical power.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per patient per 24-weeks", "timeFrame": "Baseline to end of the fixed-dose steroid treatment period (Week 24)", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "lowerLimit": "0.36", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "0.64", "lowerLimit": "0.49", "upperLimit": "0.83"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Clinically Significant Asthma Exacerbations Per Patient in the 52-week Treatment Period", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma symptoms, as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose and/or treatment with systemic rescue corticosteroids for at least 3 days. The exacerbations rate per patient was derived using Poisson model adjusted by time at risk and the following covariates: country, exacerbation history, and dose schedule. A patient's person-days at risk was taken as the total amount of time (in days) he/she spent in the 52-week treatment period.", "populationDescription": "Modified intent-to-treat population: All patients who were randomized, excluding patients from 2 sites due to Good Clinical Practice non-compliance. Excluded patients were replaced with patients at other sites to maintain statistical power.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per patient per year", "timeFrame": "Baseline to end of the treatment period (Week 52)", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.78", "lowerLimit": "0.65", "upperLimit": "0.94"}, {"groupId": "OG001", "value": "1.36", "lowerLimit": "0.92", "upperLimit": "1.71"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Daily Number of Puffs of Asthma Rescue Medication From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period", "description": "Patients were instructed to record the number of puffs of rescue medication they took twice daily in a diary. The mean daily number of puffs during the last 4 weeks of the 24-week fixed-dose steroid treatment period was calculated; for patients who discontinued prematurely, the mean of the last 28 days before discontinuation was calculated. A negative change in mean daily number of puffs indicated reduced use of rescue medication.", "populationDescription": "Modified intent-to-treat population: All patients who were randomized, excluding patients from 2 sites due to Good Clinical Practice non-compliance. Excluded patients were replaced with patients at other sites to maintain statistical power.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs", "timeFrame": "Baseline to the end (last 4 weeks) of the 24-week fixed-dose steroid treatment period", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "381"}, {"groupId": "OG001", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "2.84"}, {"groupId": "OG001", "value": "-1.0", "spread": "2.50"}]}]}]}, {"type": "SECONDARY", "title": "Change in Pediatric Asthma Quality of Life Questionnaire (Standardized) [PAQLQ(S)] Scores From Baseline to the End of the 24-week Fixed-dose Steroid Treatment Period (Week 24)", "description": "PAQLQ measures functional problems that are most troublesome to children with asthma. PAQLQ has 23 questions in 3 domains (activity limitation=5, emotional function=8, symptoms=10). Patients responded to each question on a 7-point Likert scale. Overall PAQLQ score is mean of 23 questions; each domain score is mean of questions in that domain. Minimum possible value is 1 (maximum impairment); maximum possible value is 7 (no impairment). Positive change indicated improvement. The analysis included country, baseline PAQLQ value, and dosing schedule (2-weekly/4-weekly) as factors and covariates.", "populationDescription": "Modified intent-to-treat population: All patients who were randomized, excluding patients from 2 sites due to Good Clinical Practice non-compliance. Excluded patients were replaced with patients at other sites to maintain statistical power.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline to the end of the 24-week fixed-dose steroid treatment period (Week 24)", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "375"}, {"groupId": "OG001", "value": "187"}]}], "classes": [{"title": "Activity limitation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "lowerLimit": "0.72", "upperLimit": "0.99"}, {"groupId": "OG001", "value": "0.76", "lowerLimit": "0.59", "upperLimit": "0.93"}]}]}, {"title": "Emotional function", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "lowerLimit": "0.76", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.91", "lowerLimit": "0.74", "upperLimit": "1.09"}]}]}, {"title": "Symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "lowerLimit": "0.85", "upperLimit": "1.13"}, {"groupId": "OG001", "value": "0.93", "lowerLimit": "0.76", "upperLimit": "1.10"}]}]}, {"title": "Overall (total)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.92", "lowerLimit": "0.80", "upperLimit": "1.05"}, {"groupId": "OG001", "value": "0.89", "lowerLimit": "0.73", "upperLimit": "1.05"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants With at Least 1 Adverse Event", "description": "See Adverse Events module for details.", "populationDescription": "Safety population: All patients who received any study drug and had at least 1 post-baseline safety assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to end of the study (Week 68)", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "421"}, {"groupId": "OG001", "value": "207"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90.3"}, {"groupId": "OG001", "value": "93.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Omalizumab", "description": "Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.", "seriousNumAffected": 27, "seriousNumAtRisk": 421, "otherNumAffected": 374, "otherNumAtRisk": 421}, {"id": "EG001", "title": "Placebo", "description": "Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.", "seriousNumAffected": 26, "seriousNumAtRisk": 207, "otherNumAffected": 194, "otherNumAtRisk": 207}], "seriousEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Croup infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Gastroenteritis shigella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Meningitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 207}]}, {"term": "Respiratory syncytial virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 207}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Medulloblastoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Syncope vasovagal", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 207}]}, {"term": "Bipolar disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Tic", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 207}]}, {"term": "Pneumonitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 207}]}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 207}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 207}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 207}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 59, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 207}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 207}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 207}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 207}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 207}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 51, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 207}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 117, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 56, "numAtRisk": 207}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 207}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 207}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 207}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 70, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 207}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 207}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 68, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 46, "numAtRisk": 207}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 207}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 58, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 207}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 290, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 170, "numAtRisk": 207}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 44, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 207}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 207}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 421}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 207}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M19117", "name": "Immunoglobulins, Intravenous", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M10121", "name": "Immunoglobulin E", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}]}}, "hasResults": true}